| 1 |
|
Obesity Intervention: A New Era Of Discovery And Innovation: Next-generation devices for the minimally invasive treatment of obesity not only mimic bariatric surgery, but are also designed to influence the metabolic responses that are key to losing weight, improving outcomes, and impacting chronic disease
|
Staylor, A.
|
Channing, Weinberg & Co.
|
2013
|
|
|
|
| 2 |
|
Off-Label Enforcement, Not Promotion, May See First Changes After Free Speech Ruling
|
Sutter, S.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 3 |
|
Olympus Targets A Bigger Medical Future
|
Yeo, Ashley
|
Channing, Weinberg & Co
|
2016
|
|
|
|
| 4 |
|
On The Move Personnel database featuring significant recent job changes
|
unknown
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 5 |
|
On The Move Personnel database featuring significant recent job changes
|
unknown
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 6 |
|
On The Move Significant recent job changes in pharma, medtech and diagnostics
|
unknown
|
Channing, Weinberg & Co
|
2016
|
|
|
|
| 7 |
|
On The Move Significant recent job changes in pharma, medtech and diagnostics
|
unknown
|
Channing, Weinberg & Co
|
2016
|
|
|
|
| 8 |
|
On The Move Significant recent job changes in pharma, medtech and diagnostics
|
unknown
|
Channing, Weinberg & Co
|
2015
|
|
|
|
| 9 |
|
Onyx's Transformative Year: From Productive Partner To Big Cap Contender?: Onyx is working to execute on two launches and produce late-stage data that will enable it to add more indications to its growing roster of marketed drugs. If it succeeds, it could eventually rival competitor Celgene as one of the few biotechs to move from a small cap into the big cap ranks, but any stumbles could slow or eliminate its evolution
|
Lawrence, S.
|
Channing, Weinberg & Co.
|
2013
|
|
|
|
| 10 |
|
Option Deal Structure Works For Myriad As It Moves To Buy Crescendo
|
Ratner, M.
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 11 |
|
Orphans Should Live Alone
|
Gilbert, Alain J.; Demange, Anne-Sophie; Ratner, Mark
|
Channing, Weinberg & Co
|
2016
|
|
|
|
| 12 |
|
Orthofix Spin-Out Presents Another Opportunity For Private Equity
|
Stuart, M.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 13 |
|
OUT OF THE BLOCKS Artemes Technologies, Audentes Therapeutics, Eboo Pharmaceuticals, Forendo Pharma, Liberate Medical, and Sensulin
|
unknown
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 14 |
|
OUT OF THE BLOCKS Asceneuron, BioMotiv, Intact Vascular, IntelliRad Control, Katama Pharmaceuticals, and Soulor Surgical
|
unknown
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 15 |
|
Out Of The Blocks BioHaven Pharmaceutical, Eve Medical, Inotrem, Medallion Therapeutics, and Oricula Therapeutics
|
unknown
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 16 |
|
Out of The Blocks Clementia Pharmaceuticals, EmboMedics, NightstaRx, SixOne Solutions, and Theracule
|
unknown
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 17 |
|
Out Of The Blocks Dimension Therapeutics, Envisia Therapeutics, Lewcardia, Nyxoah, and Protego Medical
|
unknown
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 18 |
|
Out Of The Blocks Dual Therapeutics, Gecko Biomedical, Pulmocide, St. Teresa Medical, and Telephus Medical
|
unknown
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 19 |
|
Out Of The Wilderness: A Second Chance For Neuropsychiatric R&D?
|
Goodman, M.
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 20 |
|
Overcoming The Bias Against Medtech Entrepreneurship In Europe: An Interview With Martin Rothman: Why are European physicians so far ahead of the curve when it comes to innovative clinical practice, and so far behind when it comes to creating companies? Interventional cardiologist and serial entrepreneur Martin Rothman offers some answers
|
Cassak, D.
|
Channing, Weinberg & Co.
|
2013
|
|
|
|
기사
(23)
